Literature DB >> 15784558

Lipopolysaccharide preparation extracted from Porphyromonas gingivalis lipoprotein-deficient mutant shows a marked decrease in toll-like receptor 2-mediated signaling.

Yasuyuki Asai1, Masahito Hashimoto, Hansel M Fletcher, Kensuke Miyake, Shizuo Akira, Tomohiko Ogawa.   

Abstract

We recently demonstrated that a new PG1828-encoded lipoprotein (PG1828LP) was able to be separated from a Porphyromonas gingivalis lipopolysaccharide (LPS) preparation, and we found that it exhibited strong cell activation, similar to that of Escherichia coli LPS, through a Toll-like receptor 2 (TLR2)-dependent pathway. In order to determine the virulence of PG1828LP toward cell activation, we generated a PG1828-deficient mutant of P. gingivalis strain 381 by allelic exchange mutagenesis using an ermF-ermAM antibiotic resistance cassette. A highly purified preparation of LPS from a PG1828-deficient mutant (DeltaPG1828-LPS) showed nearly the same ladder-like patterns in silver-stained gels as a preparation of LPS from a wild-type strain (WT-LPS), as well as Limulus amoebocyte lysate activities that were similar to those of the WT-LPS preparation. However, the ability of the DeltaPG1828-LPS preparation to activate NF-kappaB in TLR2-expressing cells was markedly attenuated. Cytokine production by human gingival fibroblasts was also decreased in response to the DeltaPG1828-LPS preparation in comparison with the WT-LPS preparation, and the activity was comparable to the stimulation of highly purified lipid A of P. gingivalis by TLR4. Further, lethal toxicity was rarely observed following intraperitoneal injection of the PG1828-deficient mutant into mice compared to that with the wild-type strain, while the DeltaPG1828-LPS preparation showed no lethal toxicity. Taken together, these results clearly indicate that PG1828LP plays an essential role in inflammatory responses and may be a major virulence factor of P. gingivalis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15784558      PMCID: PMC1087447          DOI: 10.1128/IAI.73.4.2157-2163.2005

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  43 in total

Review 1.  Porphyromonas gingivalis gingipains: the molecular teeth of a microbial vampire.

Authors:  N M O-Brien-Simpson; P D Veith; S G Dashper; E C Reynolds
Journal:  Curr Protein Pept Sci       Date:  2003-12       Impact factor: 3.272

2.  Separation and structural analysis of lipoprotein in a lipopolysaccharide preparation from Porphyromonas gingivalis.

Authors:  Masahito Hashimoto; Yasuyuki Asai; Tomohiko Ogawa
Journal:  Int Immunol       Date:  2004-08-23       Impact factor: 4.823

3.  Porphyromonas gingivalis lipopolysaccharide contains multiple lipid A species that functionally interact with both toll-like receptors 2 and 4.

Authors:  Richard P Darveau; Thu-Thao T Pham; Kayde Lemley; Robert A Reife; Brian W Bainbridge; Stephen R Coats; William N Howald; Sing Sing Way; Adeline M Hajjar
Journal:  Infect Immun       Date:  2004-09       Impact factor: 3.441

4.  OspC facilitates Borrelia burgdorferi invasion of Ixodes scapularis salivary glands.

Authors:  Utpal Pal; Xiaofeng Yang; Manchuan Chen; Linda K Bockenstedt; John F Anderson; Richard A Flavell; Michael V Norgard; Erol Fikrig
Journal:  J Clin Invest       Date:  2004-01       Impact factor: 14.808

5.  Characterization of two outer membrane protein antigens of Porphyromonas gingivalis that are protective in a murine lesion model.

Authors:  B C Ross; L Czajkowski; K L Vandenberg; S Camuglia; J Woods; C Agius; R Paolini; E Reynolds; I G Barr
Journal:  Oral Microbiol Immunol       Date:  2004-02

6.  Porphyromonas gingivalis lipopolysaccharide antagonizes Escherichia coli lipopolysaccharide at toll-like receptor 4 in human endothelial cells.

Authors:  Stephen R Coats; Robert A Reife; Brian W Bainbridge; T Thu-Thao Pham; Richard P Darveau
Journal:  Infect Immun       Date:  2003-12       Impact factor: 3.441

7.  Oral treponemes and their outer membrane extracts activate human gingival epithelial cells through toll-like receptor 2.

Authors:  Yasuyuki Asai; Takayoshi Jinno; Tomohiko Ogawa
Journal:  Infect Immun       Date:  2003-02       Impact factor: 3.441

Review 8.  Toll-like receptors.

Authors:  Kiyoshi Takeda; Tsuneyasu Kaisho; Shizuo Akira
Journal:  Annu Rev Immunol       Date:  2001-12-19       Impact factor: 28.527

9.  The two murein lipoproteins of Salmonella enterica serovar Typhimurium contribute to the virulence of the organism.

Authors:  J Sha; A A Fadl; G R Klimpel; D W Niesel; V L Popov; A K Chopra
Journal:  Infect Immun       Date:  2004-07       Impact factor: 3.441

10.  GNA33 of Neisseria meningitidis is a lipoprotein required for cell separation, membrane architecture, and virulence.

Authors:  Jeannette Adu-Bobie; Pietro Lupetti; Brunella Brunelli; Dan Granoff; Nathalie Norais; Germano Ferrari; Guido Grandi; Rino Rappuoli; Mariagrazia Pizza
Journal:  Infect Immun       Date:  2004-04       Impact factor: 3.441

View more
  24 in total

1.  Free lipid A isolated from Porphyromonas gingivalis lipopolysaccharide is contaminated with phosphorylated dihydroceramide lipids: recovery in diseased dental samples.

Authors:  Frank C Nichols; Bekim Bajrami; Robert B Clark; William Housley; Xudong Yao
Journal:  Infect Immun       Date:  2011-12-05       Impact factor: 3.441

2.  The native 67-kilodalton minor fimbria of Porphyromonas gingivalis is a novel glycoprotein with DC-SIGN-targeting motifs.

Authors:  Amir E Zeituni; William McCaig; Elizabeth Scisci; David G Thanassi; Christopher W Cutler
Journal:  J Bacteriol       Date:  2010-06-18       Impact factor: 3.490

3.  Porphyromonas gulae Activates Unprimed and Gamma Interferon-Primed Macrophages via the Pattern Recognition Receptors Toll-Like Receptor 2 (TLR2), TLR4, and NOD2.

Authors:  James A Holden; Neil M O'Brien-Simpson; Jason C Lenzo; Rebecca K H Orth; Ashley Mansell; Eric C Reynolds
Journal:  Infect Immun       Date:  2017-08-18       Impact factor: 3.441

4.  Serine dipeptide lipids of Porphyromonas gingivalis inhibit osteoblast differentiation: Relationship to Toll-like receptor 2.

Authors:  Yu-Hsiung Wang; Reza Nemati; Emily Anstadt; Yaling Liu; Young Son; Qiang Zhu; Xudong Yao; Robert B Clark; David W Rowe; Frank C Nichols
Journal:  Bone       Date:  2015-09-25       Impact factor: 4.398

Review 5.  Manifold mechanisms of Toll-like receptor-ligand recognition.

Authors:  Ken J Ishii; Cevayir Coban; Shizuo Akira
Journal:  J Clin Immunol       Date:  2005-11       Impact factor: 8.317

6.  Inflammatory cytokines are suppressed by light-emitting diode irradiation of P. gingivalis LPS-treated human gingival fibroblasts: inflammatory cytokine changes by LED irradiation.

Authors:  HongRan Choi; WonBong Lim; InAe Kim; JiSun Kim; YoungJong Ko; Hyukil Kwon; SangWoo Kim; K M Ahsan Kabir; Xiaojie Li; Oksu Kim; YoungJoon Lee; SeoYune Kim; OkJoon Kim
Journal:  Lasers Med Sci       Date:  2011-08-04       Impact factor: 3.161

7.  Oral microbial biofilm stimulation of epithelial cell responses.

Authors:  Rebecca Peyyala; Sreenatha S Kirakodu; Karen F Novak; Jeffrey L Ebersole
Journal:  Cytokine       Date:  2012-01-21       Impact factor: 3.861

8.  Porphyromonas gingivalis lipopolysaccharide weakly activates M1 and M2 polarized mouse macrophages but induces inflammatory cytokines.

Authors:  James A Holden; Troy J Attard; Katrina M Laughton; Ashley Mansell; Neil M O'Brien-Simpson; Eric C Reynolds
Journal:  Infect Immun       Date:  2014-07-21       Impact factor: 3.441

9.  Correlation between chemical structure and biological activities of Porphyromonas gingivalis synthetic lipopeptide derivatives.

Authors:  Y Makimura; Y Asai; Y Taiji; A Sugiyama; R Tamai; T Ogawa
Journal:  Clin Exp Immunol       Date:  2006-10       Impact factor: 4.330

10.  A novel class of lipoprotein lipase-sensitive molecules mediates Toll-like receptor 2 activation by Porphyromonas gingivalis.

Authors:  Sumita Jain; Stephen R Coats; Ana M Chang; Richard P Darveau
Journal:  Infect Immun       Date:  2013-02-04       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.